NDV-01 has demonstrated a 90% overall response rate in Phase 2a for non-muscle invasive bladder cancer (NMIBC), with a Phase 3 trial planned for the first half of 2026. Sepranolone, backed by promising data in Tourette syndrome, is progressing toward a Phase 2b trial in Prader-Willi syndrome. The company benefits from a seasoned leadership team, robust product exclusivity, and a strong financial foundation.
Cyborg Score Rationale
Jefferies initiated coverage with a "Buy" recommendation on December 22, 2025, and FDA provided written feedback supporting the registrational development pathway for NDV-01. The company demonstrated strong efficacy but faces typical biotech risks as a clinical-stage developer.
Top Insights
NDV-01 Phase 2 9-month follow-up showed 92% overall response anytime (23/25) and 85% complete response at 9 months with no progression to muscle-invasive disease
Regulatory update confirmed FDA alignment on registrational studies design for NDV-01 on January 12, 2026
Stock price increased 505.04% over six months followed by 14.89% recent decrease, reflecting biotech volatility
Pricing of $100 million underwritten offering on November 4, 2025 provides cash runway
Named Competitors
Gene Therapy for Rare Genetic Disorders — Leading gene therapy developer for rare neuromuscular diseases
CNS Therapeutics — Clinical-stage biotech focused on CNS rare diseases
Therapeutic Proteins — Immuno-oncology and rare disease focus
Recent Developments
(January 2026) FDA alignment confirmed on Phase 3 registrational study design for NDV-01
(December 2025) Jefferies initiated "Buy" coverage with positive outlook
(November 2025) $100 million capital raise completed and Q3 2025 results reported with 92% response rate data